Boston Scientific Corporation (BSX) Shares Sold by Columbia Partners L L C Investment Management

Columbia Partners L L C Investment Management cut its stake in Boston Scientific Corporation (NYSE:BSX) by 17.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 129,484 shares of the medical equipment provider’s stock after selling 26,680 shares during the period. Columbia Partners L L C Investment Management’s holdings in Boston Scientific Corporation were worth $3,777,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Comerica Securities Inc. raised its holdings in Boston Scientific Corporation by 0.9% in the second quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock valued at $318,000 after buying an additional 99 shares during the period. ETRADE Capital Management LLC raised its holdings in Boston Scientific Corporation by 1.7% in the second quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock valued at $279,000 after buying an additional 171 shares during the period. BB&T Corp raised its holdings in Boston Scientific Corporation by 2.8% in the second quarter. BB&T Corp now owns 12,926 shares of the medical equipment provider’s stock valued at $359,000 after buying an additional 349 shares during the period. Krilogy Financial LLC raised its holdings in Boston Scientific Corporation by 5.9% in the second quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock valued at $213,000 after buying an additional 430 shares during the period. Finally, Wetherby Asset Management Inc. raised its holdings in Boston Scientific Corporation by 3.9% in the second quarter. Wetherby Asset Management Inc. now owns 13,788 shares of the medical equipment provider’s stock valued at $382,000 after buying an additional 523 shares during the period. 90.50% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts recently commented on the stock. UBS AG restated a “buy” rating and issued a $31.00 price target (up previously from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. BidaskClub lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. SunTrust Banks, Inc. set a $34.00 price target on shares of Boston Scientific Corporation and gave the company a “buy” rating in a report on Tuesday, October 31st. Zacks Investment Research lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Boston Scientific Corporation in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $30.77.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2017/11/17/boston-scientific-corporation-bsx-shares-sold-by-columbia-partners-l-l-c-investment-management.html.

In other Boston Scientific Corporation news, SVP Maulik Nanavaty sold 57,031 shares of Boston Scientific Corporation stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $27.28, for a total value of $1,555,805.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy A. Pratt sold 11,061 shares of Boston Scientific Corporation stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the transaction, the executive vice president now directly owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 508,864 shares of company stock valued at $14,581,669. 0.74% of the stock is currently owned by corporate insiders.

Boston Scientific Corporation (NYSE BSX) traded up $0.27 during trading on Friday, reaching $28.28. 3,846,300 shares of the company’s stock were exchanged, compared to its average volume of 6,622,902. The firm has a market capitalization of $38,463.22, a P/E ratio of 22.96, a PEG ratio of 2.16 and a beta of 1.00. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. Boston Scientific Corporation has a 1 year low of $19.67 and a 1 year high of $29.93.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, hitting analysts’ consensus estimates of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.27 earnings per share. research analysts predict that Boston Scientific Corporation will post 1.25 EPS for the current year.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply